Cited by 607Diabetes Treatment and ManagementPancreatic function and diabetesDiabetes Management and Research

Genetic cause of hyperglycaemia and response to treatment in diabetes

Pearson, Ewan R, Starkey, Bryan J, Powell, Roy J, Gribble, Fiona M, Clark, Penny M, Hattersley, Andrew T·2003·The Lancet

Abstract

Background Type 2 diabetes shows evidence of underlying heterogeneity. No studies have assessed whether different causes for diabetes change the response to oral hypoglycaemic therapy. In a few cases, patients with diabetes caused by mutations in the hepatocyte nuclear factor 1alpha (HNF-1alpha) gene have been described as sensitive to the hypoglycaemic effects of sulphonylureas. We aimed to see whether the glycaemic response to the sulphonylurea gliclazide and the biguanide metformin differed in HNF-1alpha diabetes and type 2 diabetes, and to investigate the mechanism for differences in sulphonylurea sensitivity. Methods We did a randomised crossover trial of glicazide and metformin in 36 patients, either with diabetes caused by HNF-1alpha mutations or type 2 diabetes, who were matched for body-mass index and fasting plasma glucose. The primary outcome was reduction in fasting plasma glucose. Analysis was by intention to treat. We assessed possible mechanisms for sulphonylurea sensitivity through insulin sensitivity, insulin secretory response to glucose and tolbutamide, and tolbutamide clearance. Findings Patients with HNF-1alpha diabetes had a 5.2-fold greater response to gliclazide than to metformin (fasting plasma glucose reduction 4.7 vs 0.9 mmol/L, p=0.0007) and 3.9-fold greater response to gliclazide than those with type 2 diabetes (p=0.002). Patients with HNF-1alpha diabetes had a strong insulin secretory response to intravenous tolbutamide despite a small response t…

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(03)14571-0

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pearson, E. R., Starkey, B. J., Powell, R. J., Gribble, F. M., Clark, P. M., & Hattersley, A. T.
Affiliations
  • University of Exeter (GB)
  • Royal Surrey County Hospital (GB)
  • Royal Devon and Exeter Hospital (GB)
  • Addenbrooke's Hospital (GB)
  • University Hospitals Birmingham NHS Foundation Trust (GB)
Corresponding author
Hattersley, Andrew T
Venue
The Lancet
Publisher
Elsevier BV
Published
2003-10
Volume
362
Issue
9392
Pages
1275-1281
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2162590815
Cited by
607
References
5
Citations by year
2026: 17 · 2025: 20 · 2024: 23 · 2023: 31 · 2022: 46 · 2021: 29 · 2020: 31 · 2019: 26 · 2018: 29 · 2017: 25 · 2016: 35 · 2015: 27 · 2014: 34 · 2013: 27 · 2012: 22
FWCI
13.05
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Discovery Research Portal (University of Dundee) (publishedVersion)
  • University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
  • Royal Devon and Exeter Research Repository (Royal Devon and Exeter) (submittedVersion)
Funders
Wellcome Trust
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
type 2 diabetes, gliclazide, metformin, pharmacogenetics, insulin secretion, insulin sensitivity, sulfonylurea receptor, fasting blood glucose
MeSH terms
Adult, Aged, Blood Glucose, Diabetes Mellitus, Diabetes Mellitus, Type 2, DNA-Binding Proteins, Fasting, Female, Gliclazide, Humans, Hyperglycemia, Hypoglycemic Agents, Male, Metformin, Middle Aged, Nuclear Proteins, Receptors, Drug, Transcription Factors, Potassium Channels, ATP-Binding Cassette Transporters, Potassium Channels, Inwardly Rectifying, Hepatocyte Nuclear Factor 1, Hepatocyte Nuclear Factor 1-alpha, Hepatocyte Nuclear Factor 1-beta, Sulfonylurea Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review